Finally, based on the effectiveness of emapalumab in inhibiting IFNγ, there is increasing interest in testing the drug in other IFNγ-driven conditions, such as the aforementioned GF occurring after allogeneic HSCT or in patients developing acquired severe aplastic anemia. Here, IFNG is linked to idiopathic aplastic anemia.